Articles

In December 2022, a groundbreaking law was passed granting the U.S. FDA the authority to consider data from new alternative methods in the preclinical testing phase for new drug development. Among the new methods are 3D cell cultures that mimic human tissues and organs, known as microphysiological systems (MPS). The new law aims to improve clinical outcomes while decreasing reliance on animal testing. In this article, we discuss MPS and review data showing how they can synergize with Bio-Plex Assays.

Dominique Ingato, PhD, is a faculty member at MiraCosta College’s Department of Biotechnology. As one of only fifteen community colleges in California to offer a bachelor’s degree, MiraCosta College’s bachelor’s program in biomanufacturing is breaking ground. As part of this program, Ingato runs a next-generation chromatography (NGC) teaching lab, where students receive practical, hands-on training using state-of-the-art instruments, such as the NGC Chromatography System.

With the advancement of technology, flow cytometers are now able to detect a much greater range of fluorescent dyes, facilitating the analysis of more extensive and complex multicolor immunophenotyping assays. But this has also introduced more pitfalls to navigate during the design of these experiments. Find out how StarBright Dyes can help circumvent many of these issues, enabling consistent and reliable results.

The realm of druggable targets has expanded significantly with the advent of mRNA therapeutics. Scientists require exceptional accuracy and confidence to adequately characterize these therapeutics and their anticipated effects. To this end, Droplet Digital PCR (ddPCR) technology has proven invaluable. With unparalleled precision and absolute quantification, Droplet Digital PCR is revolutionizing the field of mRNA therapeutic development and manufacturing.

RNA sequencing (RNA-Seq) is a fundamental discovery technique for determining the expression patterns of encoded genes. RNA-Seq has led to innumerable breakthroughs across disciplines; however, a need remains for new sequencing and library preparation technologies to address gaps in current methods. Read how improved access to RNA-Seq would benefit translational research and how a novel RNA library preparation chemistry can synergize with new sequencing platforms.

In this webinar, see how a Bio-Plex Pro Assay could provide a high-throughput culture-free NT50 determination method for current and future SARS-CoV-2 variants.

Christien Bowman, MSc, has traversed a path from psychology to neuroscience, and is now working on attaining his PhD in biomedicine. In this interview, we discussed how Bowman uses Chelex 100 Resin as part of a fast and cost-effective method to determine the sex of zebra finch songbirds. This work ultimately helps Bowman study a behavioral paradigm that creates autism-like features in songbirds.

When it comes to tumor profiling, the poor quality and degradation of RNA in formalin-fixed paraffin-embedded (FFPE) samples are major limitations. To overcome this challenge, we tested a novel RNA-Seq workflow using the SEQuoia Complete Library Prep Kit and the SEQuoia Ribodepletion Kit. This workflow offers more complex transcriptome profiling, including both long and short RNA biotypes, to better represent the complete transcriptome.

Chimeric antigen receptor (CAR) T cells represent the next generation of therapeutic interventions and are a major advancement in personalized disease treatment. CAR T-cell therapies utilize a patient’s own T cells to recognize and destroy cancer cells or other disease-causing cells. Find out how the ZE5 Cell Analyzer has helped overcome some of the challenges associated with development of these powerful new therapies.

Historically, five-year survival rates have been used to evaluate cancer therapeutic effectiveness in clinical trials. But time is critical for research — and for patients. Fortunately, there is a promising method for evaluating cancer therapeutic effectiveness that could potentially offer prognostic insights after just one year. Noninvasive liquid biopsy analysis, including analysis of circulating tumor DNA, is improving researchers’ ability to detect clinical responses more rapidly.